Short Interest in Exicure, Inc. (NASDAQ:XCUR) Declines By 19.8%

Exicure, Inc. (NASDAQ:XCUR) saw a significant drop in short interest in April. As of April 15th, there was short interest totalling 27,500 shares, a drop of 19.8% from the March 31st total of 34,300 shares. Approximately 3.3% of the company’s shares are short sold. Based on an average daily volume of 41,100 shares, the days-to-cover ratio is presently 0.7 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Exicure stock. Geode Capital Management LLC acquired a new stake in Exicure, Inc. (NASDAQ:XCUR) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 12,645 shares of the company’s stock, valued at approximately $173,000. Geode Capital Management LLC owned approximately 0.48% of Exicure at the end of the most recent quarter. 42.82% of the stock is owned by institutional investors.

Exicure Trading Up 7.6 %

Shares of Exicure stock opened at $10.73 on Friday. Exicure has a 12 month low of $1.44 and a 12 month high of $36.00. The company has a market capitalization of $67.79 million, a PE ratio of -5.18 and a beta of 3.74. The stock’s fifty day simple moving average is $11.65 and its 200 day simple moving average is $11.48.

Exicure (NASDAQ:XCUR) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($3.39) earnings per share for the quarter.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.